http://www.biofocus.com/news/news.htmThe latest headlines and articles from BiofocusBioFocus announced today that it has launched its Academic Engagement initiative (AEi). Based on years of experience working with academic and non-profit institutions, the primary aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups, and to provide an effective and user-friendly mechanism to progress these ideas towards high quality chemical matter.http://www.biofocus.com/news/news,biofocus-launches-academic-engagement-initiative_271.htmWed, 01 May 2013 09:42:00 GMTBioFocus announced today that it has extended its collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Based on the success of the project to date, BioFocus will continue the optimization of agents for disease specific biomarkers.http://www.biofocus.com/news/news,biofocus-extends-its-collaboration-with-the-michael-j-fox-foundation_270.htmWed, 17 Apr 2013 08:52:00 GMThttp://www.biofocus.com/news/news,peter-rehse-joins-biofocus-as-senior-director-structural-biology_269.htmMon, 11 Feb 2013 09:34:00 GMTBioFocus and ChanTest today announced an agreement which will enable BioFocus to offer ChanTest’s extensive cell line library (> 200 products) and Channel Panel™ profiling services.http://www.biofocus.com/news/news,biofocus-expands-ion-channel-offering-through-agreement-with-chantest_268.htmWed, 06 Feb 2013 08:46:00 GMTBioFocus announced today the achievement of a major development milestone under their provision of medicinal chemistry services agreement with UCB. In August 2008, BioFocus and UCB entered into a drug discovery and development agreement to identify next generation treatments for severe diseases.http://www.biofocus.com/news/news,biofocus-achieves-milestone-in-its-drug-discovery-collaboration-with-ucb_261.htmTue, 04 Dec 2012 08:50:00 GMTActiviomics today announces it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin. Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems. This agreement was signed as part of Activiomics’ recently announced strategic partnership with BioFocus.http://www.biofocus.com/news/news,activiomics-signs-research-agreement-with-kyowa-hakko-kirin-as-part-of-its-strategic-partnership-with-biofocus_260.htmThu, 22 Nov 2012 08:46:00 GMTGalapagos NV (Euronext: GLPG) announced today that its service division BioFocus and Ono Pharmaceutical Co., Ltd. (Osaka Japan) have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client. Financial details were undisclosed.http://www.biofocus.com/news/news,galapagos-subsidiary-biofocus-and-ono-sign-a-drug-discovery-agreement-in-the-field-of-cns-disorders_250.htmMon, 03 Sep 2012 09:01:00 GMTBioFocus and Activiomics today announced a strategic alliance which will allow BioFocus to offer its customers Activiomics’ proteomics services to improve identification of novel targets for drug discovery and biomarkers for diagnostics.http://www.biofocus.com/news/news,biofocus-expands-its-drug-discovery-offering-with-proteomics-technology-from-activiomics_247.htmWed, 25 Jul 2012 08:36:00 GMTAs part of maintaining its position as a leading provider of screening services, BioFocus has selected Titian Software’s industry-leading Mosaic™ sample management software to provide fast and easy access to its 900,000 compounds, one of the largest HTS compound collections of any CRO in the world.http://www.biofocus.com/news/news,biofocus-selects-titians-mosaic-software-to-provide-optimized-screening-services_245.htmTue, 10 Jul 2012 08:42:00 GMTGalapagos NV (Euronext: GLPG) and Ono Pharmaceutical Co., Ltd. (TSE: 4528) announced today that they have signed an additional collaboration agreement focused on discovering novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma.http://www.biofocus.com/news/news,ono-and-galapagos-subsidiary-biofocus-sign-an-additional-target-discovery-agreement-in-the-field-of-allergic-disease_244.htmWed, 30 May 2012 08:15:00 GMTGalapagos’ service companies, BioFocus and Argenta, today announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases.http://www.biofocus.com/news/news,biofocus-and-argenta-announce-drug-discovery-collaboration-with-astrazeneca-in-respiratory-and-inflammatory-disease_235.htmWed, 14 Mar 2012 08:46:00 GMTAlmirall, S.A. announced today that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV (Euronext: GLPG). The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort. The value of this collaboration to BioFocus could reach €7.5 million.http://www.biofocus.com/news/news,almirall-and-biofocus-enter-research-alliance_227.htmWed, 25 Jan 2012 08:48:00 GMTBioFocus, an integrated drug discovery partner, today announced that it has enhanced its diverse screening library through new compound supply agreements with InterBioScreen, Enamine and ChemBridge. BioFocus now offers one of the most powerful screening platforms in the industry with over 900,000 unique chemical compounds and approximately 100,000 probes from natural sources.http://www.biofocus.com/news/news,biofocus-creates-novel-diverse-screening-library_215.htmMon, 05 Dec 2011 08:42:00 GMTBarcelona, Spain, and Saffron Walden, UK, November 15, 2011. The pharmaceutical company Almirall S.A. and BioFocus, an integrated drug discovery partner, today announced they have entered into a collaboration agreement to find new hit compounds against key targets of interest to Almirall.http://www.biofocus.com/news/news,almirall-and-biofocus-announce-collaboration-to-find-new-hit-compounds-against-key-targets_213.htmTue, 15 Nov 2011 10:02:00 GMTBioFocus announced today that it has extended its collaboration with Chiesi Farmaceutici, a privately owned Italian pharmaceutical company, for a second time. This extension of the collaboration with Chiesi is valued at €2.8 million.http://www.biofocus.com/news/news,biofocus-announces-second-extension-to-collaboration-with-chiesi_209.htmWed, 12 Oct 2011 06:34:00 GMTGalapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million).http://www.biofocus.com/news/news,argenta-and-biofocus-announce-twoyear-extension-of-drug-discovery-collaboration-with-genentech_207.htmThu, 18 Aug 2011 06:30:00 GMTBioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.http://www.biofocus.com/news/news,biofocus-and-intermed-discovery-announce-marketing-collaboration_205.htmTue, 19 Jul 2011 08:12:00 GMTBioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.http://www.biofocus.com/news/news,biofocus-enters-collaboration-with-michael-j-fox-foundation_204.htmWed, 13 Jul 2011 08:25:00 GMTBioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision.http://www.biofocus.com/news/news,biofocus-extends-collaboration-with-usher-iii-initiative_202.htmTue, 21 Jun 2011 09:29:00 GMTEvotec AG (Frankfurt Stock Exchange: EVT; TecDAX) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company. http://www.biofocus.com/news/news,evotec-acquires-compound-management-business-from-galapagos_200.htmWed, 01 Jun 2011 09:07:00 GMT(c) 2013, Biofocus. All rights reserved.5